In this episode of Stock Spotlight, Michael dives deep into Veeva Systems, the vertically integrated SaaS platform powering critical workflows across the life sciences industry. From clinical trials and regulatory compliance to commercial CRM and embedded data analytics, Veeva has become the operating system for biopharma, delivering elite margins, strong free cash flow per share and a wide economic moat built on high switching costs and regulated environments.

Michael explore Veeva’s growth drivers, including rapid expansion in R&D solutions, emerging AI-powered workflows and long-term optionality within a $20B+ TAM, while also addressing the key risks facing the stock today: increasing CRM competition from Salesforce and the ultimate long-term impact of AI.

Using a quality-focused fundamental framework combined with valuation and technical analysis, I break down why Veeva remains a high-quality compounder, what metrics investors should monitor and whether the current setup presents an attractive long-term opportunity.

----------------------------------------------------------------

00:00 Intro

00:38 Investment Checklist & Database

01:17 Business Overview

09:22 Industry Overview

14:41 Quality Growth Profile

17:55 Financial Statement Overview

22:47 Leadership & Incentives

28:15 KPIs to Track

29:26 Valuation & Technical Analysis

33:49 Verdict

36:54 Outro

----------------------------------------------------------------

Intro Music: Andrey Rossi – Seize the Day

Outro Music: Ra – Prospect

*Music provided by Uppbeat Premium

Follow me on X: ⁠https://x.com/invest091⁠

Subscribe to my YouTube channel: https://www.youtube.com/@stockspotlightpodcast

----------------------------------------------------------------

Disclosure: The host of Stock Spotlight is not a licensed financial advisor. The information and opinions shared during the show are for entertainment purposes only.